Table 3.
Promter Hypermethylation and cervical cancer survival
| Alive | Dead | Hazard Ratio§ | 95%CI | ||
| Total loci | 0 | 9 | 2 | 1.00 | – |
| 1 | 6 | 9 | 0.75 | 0.14–4.00 | |
| 2 | 13 | 19 | 1.04 | 0.20–5.50 | |
| ≥3 | 11 | 13 | 1.07 | 0.19–5.92 | |
| CDH1 | + | 18 | 27 | 0.69 | 0.29–1.63 |
| - | 21 | 16 | 1.00 | – | |
| DAPK | + | 19 | 18 | 0.53 | 0.23–1.19 |
| - | 20 | 25 | 1.00 | – | |
| RARB | + | 8 | 16 | 1.66 | 0.80–3.46 |
| - | 31 | 27 | 1.00 | – | |
| HIC1 | + | 7 | 8 | 1.67 | 0.69–4.04 |
| - | 32 | 35 | 1.00 | – | |
| FHIT | + | 3 | 6 | 1.18 | 0.38–3.66 |
| - | 36 | 37 | 1.00 | – | |
| RASSF1A | + | 5 | 1 | 2.02 | 0.16–25.08 |
| - | 34 | 42 | 1.00 | – | |
| APC | + | 4 | 5 | 0.70 | 0.21–2.41 |
| - | 35 | 38 | 1.00 | – | |
| CDKN2A | + | 2 | 5 | 1.64 | 0.51–5.26 |
| - | 37 | 38 | 1.00 | – | |
| MGMT | + | 0 | 4 | 2.30 | 0.46–11.45 |
| - | 39 | 39 | 1.00 | – | |
| BRCA1 | + | 0 | 5 | 3.05 | 0.72–12.93 |
| - | 39 | 38 | 1.00 | – |
Adjusted for age (continuous), treatment (3 groups), tumor size (binary), stage (3 groups) and HPV type (4 groups)